NASDAQ:BTAI - BioXcel Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $102.00
  • Forecasted Upside: 310.30 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.08 (-4.16%)

This chart shows the closing price for BTAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioXcel Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BTAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BTAI

Analyst Price Target is $102.00
▲ +310.30% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for BioXcel Therapeutics in the last 3 months. The average price target is $102.00, with a high forecast of $140.00 and a low forecast of $60.00. The average price target represents a 310.30% upside from the last price of $24.86.

This chart shows the closing price for BTAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in BioXcel Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/28/2021HC WainwrightLower Price TargetBuy$176.00 ➝ $140.00Low
6/23/2021Truist SecuritiesLower Price TargetBuy$128.00 ➝ $125.00High
6/1/2021HC WainwrightBoost Price TargetBuy$170.00 ➝ $176.00High
5/11/2021HC WainwrightLower Price TargetBuy$175.00 ➝ $170.00High
4/9/2021Berenberg BankInitiated CoverageBuy$75.00Low
4/1/2021TruistLower Price Target$150.00 ➝ $127.00High
4/1/2021Truist SecuritiesLower Price TargetBuy$150.00 ➝ $127.00High
4/1/2021HC WainwrightLower Price TargetBuy$185.00 ➝ $175.00High
4/1/2021Canaccord GenuityLower Price TargetBuy$110.00 ➝ $95.00High
2/1/2021UBS GroupInitiated CoverageBuy$99.00Low
1/6/2021HC WainwrightBoost Price TargetBuy$175.00 ➝ $185.00N/A
12/28/2020Truist FinancialReiterated RatingBuyN/A
11/18/2020Canaccord GenuityBoost Price TargetBuy$108.00 ➝ $110.00High
10/30/2020The Goldman Sachs GroupInitiated CoverageBuy$60.00High
9/2/2020Jefferies Financial GroupInitiated CoverageBuy$82.00 ➝ $82.00High
8/17/2020GuggenheimBoost Price TargetBuy$101.00 ➝ $122.00High
8/17/2020BMO Capital MarketsLower Price TargetOutperform$104.00 ➝ $95.00High
8/17/2020HC WainwrightLower Price TargetBuy$200.00 ➝ $175.00High
8/14/2020Canaccord GenuityReiterated RatingBuy$120.00 ➝ $108.00High
7/21/2020Canaccord GenuityBoost Price TargetPositive ➝ Buy$71.00 ➝ $120.00Medium
7/20/2020BMO Capital MarketsBoost Price TargetOutperform ➝ Positive$64.00 ➝ $104.00High
7/20/2020HC WainwrightBoost Price TargetBuy$120.00 ➝ $200.00High
7/13/2020Bank of AmericaBoost Price TargetBuy$53.00 ➝ $63.00High
7/6/2020HC WainwrightReiterated RatingBuy$120.00High
6/24/2020HC WainwrightReiterated RatingBuy$95.00Medium
6/11/2020HC WainwrightReiterated RatingBuy$95.00Medium
6/4/2020GuggenheimInitiated CoverageBuy$101.00High
5/13/2020HC WainwrightReiterated RatingBuy$95.00High
5/13/2020Canaccord GenuityReiterated RatingBuy$71.00High
5/1/2020Canaccord GenuityReiterated RatingBuy$68.00High
4/28/2020HC WainwrightReiterated RatingBuy$95.00High
4/1/2020Bank of AmericaInitiated CoverageBuy$45.00High
3/19/2020HC WainwrightReiterated RatingBuy$95.00High
3/10/2020BMO Capital MarketsBoost Price Target$26.00 ➝ $64.00High
3/10/2020Canaccord GenuityReiterated RatingBuyLow
2/5/2020HC WainwrightReiterated RatingBuy$30.00High
1/16/2020BMO Capital MarketsReiterated RatingOutperform ➝ Positive$26.00High
1/8/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $30.00High
12/31/2019Canaccord GenuityBoost Price TargetBuy$24.00 ➝ $27.00Low
12/30/2019HC WainwrightInitiated CoverageBuy$25.00High
12/11/2019HC WainwrightReiterated RatingBuy$25.00High
11/20/2019HC WainwrightReiterated RatingBuy$25.00Medium
11/12/2019SunTrust BanksInitiated CoverageBuy$24.00High
9/18/2019BMO Capital MarketsSet Price TargetBuy$21.00Low
8/21/2019HC WainwrightSet Price TargetBuy$25.00Low
6/5/2019HC WainwrightSet Price TargetBuy$25.00Low
5/28/2019HC WainwrightSet Price TargetBuy$25.00Medium
3/26/2019HC WainwrightSet Price TargetBuy$25.00High
3/8/2019Canaccord GenuitySet Price TargetBuy$21.00High
3/5/2019HC WainwrightSet Price TargetBuy$25.00Medium
2/5/2019HC WainwrightSet Price TargetBuy$25.00High
1/4/2019HC WainwrightReiterated RatingBuy$25.00Medium
12/12/2018HC WainwrightReiterated RatingBuy$25.00Medium
8/10/2018Canaccord GenuityReiterated RatingBuy$21.00Low
8/1/2018HC WainwrightReiterated RatingBuy$25.00Low
7/3/2018Canaccord GenuityReiterated RatingBuy$21.00High
6/12/2018HC WainwrightReiterated RatingBuy$25.00High
5/3/2018HC WainwrightInitiated CoverageBuy$25.00High
4/2/2018Canaccord GenuityInitiated CoverageBuy$21.00High
4/2/2018BMO Capital MarketsInitiated CoverageOutperform$23.00High
4/2/2018UBS GroupInitiated CoverageBuy$18.00High
4/2/2018BarclaysInitiated CoverageOverweight ➝ Overweight$15.00High
(Data available from 7/25/2016 forward)
BioXcel Therapeutics logo
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $24.86
Low: $24.72
High: $25.78

50 Day Range

MA: $31.78
Low: $24.86
High: $38.83

52 Week Range

Now: $24.86
Low: $24.72
High: $67.74


255,628 shs

Average Volume

490,036 shs

Market Capitalization

$612.30 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of BioXcel Therapeutics?

The following sell-side analysts have issued reports on BioXcel Therapeutics in the last year: Berenberg Bank, BMO Capital Markets, Canaccord Genuity, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., The Goldman Sachs Group, Inc., Truist, Truist Financial Co., Truist Securities, and UBS Group AG.
View the latest analyst ratings for BTAI.

What is the current price target for BioXcel Therapeutics?

10 Wall Street analysts have set twelve-month price targets for BioXcel Therapeutics in the last year. Their average twelve-month price target is $102.00, suggesting a possible upside of 310.3%. HC Wainwright has the highest price target set, predicting BTAI will reach $140.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $60.00 for BioXcel Therapeutics in the next year.
View the latest price targets for BTAI.

What is the current consensus analyst rating for BioXcel Therapeutics?

BioXcel Therapeutics currently has 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BTAI will outperform the market and that investors should add to their positions of BioXcel Therapeutics.
View the latest ratings for BTAI.

What other companies compete with BioXcel Therapeutics?

How do I contact BioXcel Therapeutics' investor relations team?

BioXcel Therapeutics' physical mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company's listed phone number is 475-238-6837 and its investor relations email address is [email protected] The official website for BioXcel Therapeutics is